

01/16/02

1653

Please type a plus sign (+) inside this box → ☒PTD/SB/21 (08-00)  
Approved for use through 10/31/2002. DMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid DMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	09/446,543	
	Filing Date	December 20, 1999	
	First Named Inventor	S. HINUMA	
	Group Art Unit	1653	
	Examiner Name	R. Mitra	
Total Number of Pages in This Submission	5	Attorney Docket Number	2472 USOP

JAN 22 2002

RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard.
Remarks		The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Elaine M. Ramesh, Ph.D., JD, Reg. No. 43, 032
Signature	<i>Elaine M Ramesh</i>
Date	October 26, 2001

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: \_\_\_\_\_

Typed or printed name			
Signature		Date	



Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express mail #EL 742689101 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/446,543  
Filed: December 20, 1999  
Inventor: S. Hinuma  
For: Prolactin Secretion Modulator  
Atty. Dkt. No. 2472 USOP

Art Unit: 1653  
Examiner: R. Mitra  
Allowed:   
Batch:   
Paper No.: 12

TECH CENTER 1600/2900

JAN 22 2002

RECEIVED

Election of Claims

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed September 28, 2001, Applicants elect to prosecute Group I (claims 1-4, 6, 10, 11, 13 and 14) in the present application.

Provisional election of the sequence SEQ ID NO: 61, and the disease of hypoovarianism are also made.

No amendment of inventorship is necessitated by this election.


Applicants make the election with traverse. The agents and uses thereof identified as the claims of group I and the uses for those same agents identified as the claims of groups II, III and IV are sufficiently related so as not to unduly burden the Examiner in making a search.

Early allowance of the claims is requested. Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, she is respectfully invited to call Applicants' attorney at the number below.

Respectfully submitted,

Dated: October 26, 2001

(847) 383-3391  
(847) 383-3372

  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Mark Chao, Ph.D., Reg. No. 37,293  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

**Certificate of Mailing under 37 CFR 1.10**

The undersigned hereby certifies that this document, along with any attachments, is being deposited in an envelope addressed to The Commissioner of Patents and Trademarks, with sufficient postage with the United States Postal Service EXPRESS MAIL Post Office to Addressee Service on this date October 26, 2001.

Express Mail Label No. EL 792689101 US

Gail L. Winokur  
Printed Name: Gail L. Winokur